Therapy

AKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case

Retrieved on: 
Sabato, Maggio 4, 2024
Cirrhosis, EFX, Liver disease, Fatty liver disease, NASH, Patient, Therapy, SAN, Food and Drug Administration, Tobacco

), the Akero class action lawsuit charges Akero as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Akero class action lawsuit charges Akero as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Akero class action lawsuit must be filed with the court no later than June 25, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the Akero class action lawsuit.
  • An investor’s ability to share in any potential future recovery of the Akero class action lawsuit is not dependent upon serving as lead plaintiff.

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Retrieved on: 
Venerdì, Maggio 3, 2024
Cancer, Abstract, Cell, ADR, Patient, Gene, Society, IPSC, SLE, Therapy, SAN

SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.

Key Points: 
  • SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.
  • At the ASGCT conference, the Company will present multiple preclinical studies displaying the function of FT522 using peripheral blood mononuclear cells (PBMCs) sourced from unmatched donors with systemic lupus erythematosus (SLE).
  • These preclinical data demonstrate rapid and deep B-cell depletion, enhanced functional persistence, and elimination of alloreactive host immune cells, indicating that FT522 may deliver therapeutic benefit to patients with autoimmune diseases without requiring administration of conditioning chemotherapy.
  • Late-breaking abstracts are available on the ASGCT Annual Meeting website .

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

Retrieved on: 
Venerdì, Maggio 3, 2024
Titan, Sale, Idiopathic pulmonary fibrosis, Prospectus, Aileron, ALRN, Security (finance), Form, Exercise, Patient, Fibrosis, S-3, Therapy

Each share of common stock and accompanying warrant were sold together at a combined public offering price of $4.68.

Key Points: 
  • Each share of common stock and accompanying warrant were sold together at a combined public offering price of $4.68.
  • The aggregate gross proceeds of the offering were approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aileron, and excluding any proceeds that may be received from exercise of the warrants.
  • Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.
  • The offering was made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement.

BetterLife Announces Intent to Complete Private Placement of Units

Retrieved on: 
Venerdì, Maggio 3, 2024
Therapy, Lysergic acid diethylamide, LSD, DSM-IV codes, Private

VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to complete a Non-Brokered Private Placement offering (the “Private Placement”) of up to $500,000.

Key Points: 
  • VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to complete a Non-Brokered Private Placement offering (the “Private Placement”) of up to $500,000.
  • The Company intends to use the proceeds for the advancement of its lead compound BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide), and general working capital purposes.
  • The Private Placement will be issued in units, pursuant to the offering, with each unit comprised of one common share and one common share purchase warrant having a term of two years from the closing date of the offering.
  • The close will be announced as soon as it has completed.

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Venerdì, Maggio 3, 2024
Option, Elective surgery, Therapy, Employment, Pharmaceutical industry

The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

Key Points: 
  • The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.
  • Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.
  • Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and are otherwise subject to the terms and conditions of the equity award agreement approved by Anika.
  • The Options were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Venerdì, Maggio 3, 2024
Cardiovascular disease, Therapy, Employment

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received stock options to purchase an aggregate of 64,200 shares of the company’s common stock and an aggregate of 56,100 restricted stock units (RSUs).
  • The options have an exercise price of $6.01 per share, which is equal to the closing price of the company’s common stock on the date of grant.
  • The RSUs will vest in equal annual installments on the first four anniversaries of July 1, 2024, subject to each such employee’s continued service with the company on each such vesting date.

MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call

Retrieved on: 
Venerdì, Maggio 3, 2024
Therapy, Cancer, ID, Telephone, Webcast

ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024.

Key Points: 
  • ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024.
  • MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024, at 4:30 pm ET.
  • To participate via telephone, please register in advance at this link .
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm .

Galera Adopts Limited Duration Stockholder Rights Agreement

Retrieved on: 
Venerdì, Maggio 3, 2024
Cancer, Sidley Austin, Therapy, Rights

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests.

Key Points: 
  • MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests.
  • In addition, the Rights Agreement provides the Board with time to make informed decisions that are in the best long-term interests of Galera and its stockholders.
  • The Rights Agreement has an expiration date of May 2, 2025, and the Board will consider whether to terminate the Rights Agreement earlier than such date if warranted.
  • Except as provided in the Rights Agreement, the Board is entitled to redeem the rights at $0.001 per right.

Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock

Retrieved on: 
Venerdì, Maggio 3, 2024
Sale, Prospectus, Prader–Willi syndrome, Equity, Guggenheim Partners, PWS, Research, Nicollet Mall, Madison Avenue, Oppenheimer Holdings, Public expenditure, Form, Therapy, Tablet, Attention, Telephone, Security (finance)

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share.

Key Points: 
  • REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share.
  • The gross proceeds of the public offering are expected to be approximately $138.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
  • Soleno has also granted the underwriters a 30-day option to purchase up to 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • Piper Sandler, Guggenheim Securities, Cantor Fitzgerald & Co. and Oppenheimer & Co. are acting as joint book-running managers for the public offering.

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

Retrieved on: 
Venerdì, Maggio 3, 2024
University, Research and development, Radiation, Oncology, Research, Abstract, Immunotherapy, MD, University School, Cayetano Heredia University, Internet, Lung cancer, Radiation therapy, Johns Hopkins Hospital, International Association, Respiratory disease, Society, Lung, MD Anderson Cancer Center, Publication, Biomarker, Research institute, Esophageal cancer, Therapy, Cancer

The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D.

Key Points: 
  • The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D.
  • (MD Anderson Cancer Center), who will discuss below topics:
    Also featured will be a management discussion on technology platform and pipeline updates of SEED Therapeutics, BeyondSpring’s majority-owned molecular glue subsidiary.
  • He joined Piedmont Cancer Institute in 2011 and is the Director of Research at Piedmont Fayette Hospital.
  • Dr. Lin runs a translational research team that evaluates biomarkers for treatment response and disease outcomes after cancer therapy.